RxDoctor Payments Data

Erica Williams

Physician Assistant · Long Beach, CANPI 1164207593

Payments from drug & device makers

$6,569in general payments, 2019–2025

Across 228 payments — averaging $28.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$786
  • Sanofi$583
  • Madrigal Pharmaceuticals$551
  • Phathom Pharmaceuticals, Inc.$549
  • Ardelyx, Inc.$513
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,548100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,569 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$40,401
Medicare patients
390
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClenpiqSod Picosulf/Mag Ox/Citric Ac118$20,302
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C57$8,368
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates116$7,288
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,388
Sucralfate14$1,331
Omeprazole125$1,169
Colestipol Hcl13$851
Famotidine70$710
Pantoprazole Sodium39$700
Ondansetron OdtOndansetron15$694
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl47$642
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl16$261
Lansoprazole18$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$43$20,302118 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$145$8,36857 claims
Braintree Laboratories, Inc.Sutab$21$2,38815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →